Digital Versus Hospital Follow-Up for Heart Failure Management After Hospital Discharge
A Study Comparing Home-Based Telehealth and Outpatient Clinic Care Using the STRONG-HF Strategy
Led by University Hospital, Akershus · Updated on 2026-06-17
450
Participants Needed
11
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating if patients with acute heart failure can achieve the same level of heart failure medication management through digital follow-up at home compared to traditional hospital visits, based on the STRONG-HF strategy. This study addresses the challenge of low use of recommended heart failure therapies despite evidence showing they reduce mortality, aiming to improve care delivery by testing remote medication up-titration and follow-up. The trial builds on the STRONG-HF trials success, which showed better outcomes with early medication adjustment and follow-up in specialized clinics but faced barriers due to frequent hospital visits.
Participants will be randomly assigned to one of two groups one receiving follow-up and heart failure medication management at home via telecommunication led by specialized nurses, including home visits at 1, 2, 3, and 6 weeks plus a primary care physician visit around week 2 the other group receiving follow-up and medication management at hospital outpatient clinics on the same schedule. Both groups follow the STRONG-HF intensive care strategy with early and rapid medication up-titration to at least half the maximum tolerated doses at discharge and then to maximum tolerated doses after 2 weeks, with safety visits at weeks 1, 3, and 6.
During the 90-day study period, participants will be monitored for medication doses, heart function via echocardiography, blood tests including NT-proBNP, quality of life assessments, self-care, and patient satisfaction. Readmissions and survival will be tracked for up to 24 months. Follow-up visits occur weekly during the first 6 weeks, and researchers will assess treatment adherence, adverse events, and healthcare costs. This approach aims to reduce the burden on patients and healthcare systems while maintaining effective heart failure care.
CONDITIONS
Brief Title
Management of Patients With Heart Failure at Home After Hospital Discharge
Research Team
P
Peder L Myhre, MD, PhD
H
Henrik Schirmer, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Hospital admission within the 72 hours prior to screening for acute heart failure
NT-proBNP level of 1,000 pg/mL or higher measured during hospitalization
Systolic blood pressure of at least 100 mmHg and heart rate of at least 60 bpm within 24 hours before randomization
Serum potassium level of 5.0 mEq/L or lower
Receiving half or less of the optimal dose of ACEi/ARB/ARNi, beta-blocker, or MRA medications
Willing and able to provide written informed consent to participate
You will not qualify if you...
Age below 18 or above 85 years
Known intolerance to high doses of beta-blockers
Known intolerance to high doses of renin-angiotensin system blockers (ACEi and ARB)
Severe kidney disease or estimated glomerular filtration rate below 30 mL/min/1.73m2 at screening or history of dialysis
Participation in another heart failure intervention or investigational drug/device study within 30 days before screening
Acute heart failure caused by a completely reversible condition unlikely to lead to chronic heart failure after discharge (e.g., Takotsubo syndrome)
Severe non-adherence to medications
Psychiatric or neurological disorders, cirrhosis, or active cancer with life expectancy less than 6 months
History of heart transplant, on transplant list, or using/planned ventricular assist device
Uncorrected thyroid disease, active myocarditis, amyloid or hypertrophic obstructive cardiomyopathy
Inability to follow study requirements due to major health, social, or financial issues
Low digital competency preventing smartphone or tablet use
Language barriers requiring an external interpreter
Pregnant or nursing (lactating) women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 6 weeks
Participants receive follow-up and heart failure medication management either at home through digital visits led by specialized nurses or at hospital outpatient clinics. Medication doses are adjusted according to the STRONG-HF strategy with safety visits at 1, 3, and 6 weeks.
Visits at weeks 1, 2, 3, and 6 plus a primary care visit around week 2
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Phase 2 Study of 18F-mFBG PET Imaging
for Heart Failure Patients with Ischemic Cardiomyopathy
and Implantable Cardioverter-Defibrillators
Post-Discharge Counseling and Phone Follow-Up to Reduce Heart Failure Readmissions at Komfo Anokye Teaching Hospital
Myocardial Energetic Profiling Using 31P Magnetic Resonance Spectroscopy
and Prognostic Assessment Across Heart Failure and Cardiomyopathy Types
3D Imaging Study of Right Heart Function During Mechanical Pump Placement for Heart Failure
Evaluating Cardiac Fibrosis in Heart Failure Using 68Ga-FAPI PETCT Compared to MRI
A Pilot Study in Patients with HFrEF and HFpEF
Study of Vascular Function and Exercise Effects in Aging and Cardiovascular Diseases Including COPD and Pulmonary Hypertension
A Phase I Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Effects of Oral Doses of HRS-5765 in Healthy Adults Aged 18 to 65
Phase I Study Evaluating Safety and Pharmacokinetics of Single and Multiple Oral Doses of HRS-7156 in Healthy Adults
Optimizing Heart Failure and Chronic Kidney Disease Treatment in Elderly Patients Using Sodium Zirconium Cyclosilicate to Manage Potassium Levels
Danish Study Testing Coenzyme Q10 and Selenium Supplements to Reduce Hospitalization and Death in Heart Failure Patients
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.